1,477 results
Search Results
2. research paper Tumour cell/dendritic cell fusions as a vaccination strategy for multiple myeloma.
- Author
-
Raje, Noopur, Hideshima, Teru, Davies, Faith E., Chauhan, Dharminder, Treon, Steven P., Young, Gloria, Tai, Yu-Tzu, Avigan, David, Gong, Jianlin, Schlossman, Robert L., Richardson, Paul, Kufe, Donald W., and Anderson, Kenneth C.
- Subjects
- *
IMMUNOTHERAPY , *CANCER cells , *DENDRITIC cells , *VACCINES , *MULTIPLE myeloma , *LYMPHOCYTES , *T cells - Abstract
Multiple myeloma (MM) cells express certain tumour-associated antigens (TAAs) that could serve as targets for active-specific immunotherapy. The aim of the present study was to test the MM/dendritic cell (DC) fusion as a vaccination strategy. We fused MM cells with DC to generate fusion cells (FCs) and tested their antigen presenting cell (APC) function in mixed lymphocyte reactions and cytotoxicity assays. First, the HS Sultan and SK0-007 HAT sensitive human MM cell lines and DCs generated from peripheral blood of normal donors were fused in the presence of 50% polyethylene glycol to form FCs. Next, tumour cells freshly isolated from patients were similarly fused with autologous DCs to generate FCs. The FCs demonstrated a biphenotypic profile, confirmed both by flow-cytometry and dual immunofluorescence microscopy. These FCs induced MM-specific cytotoxicity. FCs, but not MM cells or DCs alone, were potent stimulators of autologous patient T cells. More importantly, FC-primed autologous peripheral blood mononuclear cells demonstrated major histocompatibility complex-restricted MM-specific cytolysis. These studies therefore demonstrated that MM/DC FC can trigger an autologous immune response to MM cells and formed the framework for a clinical trial currently underway. [ABSTRACT FROM AUTHOR]
- Published
- 2004
- Full Text
- View/download PDF
3. research paper Retroviral transduction of acute myeloid leukaemia-derived dendritic cells with OX40 ligand augments their antigen presenting activity.
- Author
-
Yanagita, Soshi, Hori, Toshiyuki, Matsubara, Yasushi, Ishikawa, Takayuki, and Uchiyama, Takashi
- Subjects
- *
MYELOID leukemia , *DENDRITIC cells , *LIGANDS (Biochemistry) , *ANTIGENS , *CYTOKINES , *T cells , *STEM cell transplantation - Abstract
Recent studies have shown that human myeloid leukaemia cells can differentiate into dendritic cell (DC)-like cells (leukaemia-DCs) when cultured with a combination of cytokines. In the present study, we examined whether the transduction of leukaemia-DCs with OX40 ligand (OX40L), a member of the tumour necrosis factor (TNF) family, resulted in augmentation of their antigen presenting activity. Bicistronic retroviral vectors expressing both human OX40L and enhanced green fluorescent protein (EGFP) or EGFP alone were generated and used for transduction. Fresh leukaemic cells from five patients with acute myeloid leukaemia (AML) were isolated and retrovirally transduced with OX40L during the culture with a combination of cytokines from stem cell factor, fms-like tyrosine kinase (Flt)-3 ligand, granulocyte-macrophage colony stimulating factor (GM-CSF), interleukin-4 (IL-4) and TNF- α. After 7 d, the majority of cells showed DC-like morphology, and expressed higher levels of CD80, CD86 and HLA-DR than fresh leukaemic cells. The transduction efficiency was 8·5–27·2%. Leukaemia-DCs transduced with OX40L elicited higher proliferative response of allogeneic CD4+ T cells than fresh leukaemic cells, non-transduced, or mock-transduced leukaemia-DCs. Co-culture of allogeneic CD4+ T cells with OX40L-transduced leukaemia-DCs was superior in the generation of interferon (IFN)- γ producing CD4+ T cells and in production of IFN- γ. Furthermore, OX40L-transduced leukaemia-DCs could elicit significant proliferative response of human leucocyte antigen-matched T cells from the donor in allogeneic stem cell transplantation. These results indicate that retroviral transduction of leukaemia-DCs with OX40L augments their antigen presenting cell activity and thus renders them more suitable for tumour vaccines or ex vivo stimulation of leukaemia-specific T cells. [ABSTRACT FROM AUTHOR]
- Published
- 2004
- Full Text
- View/download PDF
4. Forefronts and hotspots evolution of the nanomaterial application in anti-tumor immunotherapy: a scientometric analysis.
- Author
-
Cao, Wei, Jin, Mengyao, Zhou, Weiguo, Yang, Kang, Cheng, Yixian, Chen, Junjie, Cao, Guodong, Xiong, Maoming, and Chen, Bo
- Subjects
REGULATORY T cells ,IMMUNOLOGIC memory ,NANOSTRUCTURED materials ,IMMUNOTHERAPY ,DENDRITIC cells ,T cells - Abstract
Background: Tumor immunotherapy can not only eliminate the primary lesion, but also produce long-term immune memory, effectively inhibiting tumor metastasis and recurrence. However, immunotherapy also showed plenty of limitations in clinical practice. In recent years, the combination of nanomaterials and immunotherapy has brought new light for completely eliminating tumors with its fabulous anti-tumor effects and negligible side effects. Methods: The Core Collection of Web of Science (WOSCC) was used to retrieve and obtain relevant literatures on antitumor nano-immunotherapy since the establishment of the WOSCC. Bibliometrix, VOSviewer, CiteSpace, GraphPad Prism, and Excel were adopted to perform statistical analysis and visualization. The annual output, active institutions, core journals, main authors, keywords, major countries, key documents, and impact factor of the included journals were evaluated. Results: A total of 443 related studies were enrolled from 2004 to 2022, and the annual growth rate of articles reached an astonishing 16.85%. The leading countries in terms of number of publications were China and the United States. Journal of Controlled Release, Biomaterials, Acta Biomaterialia, Theranostics, Advanced Materials, and ACS Nano were core journals publishing high-quality literature on the latest advances in the field. Articles focused on dendritic cells and drug delivery accounted for a large percentage in this field. Key words such as regulatory T cells, tumor microenvironment, immune checkpoint blockade, drug delivery, photodynamic therapy, photothermal therapy, tumor-associated macrophages were among the hottest themes with high maturity. Dendritic cells, vaccine, and T cells tend to become the popular and emerging research topics in the future. Conclusions: The combined treatment of nanomaterials and antitumor immunotherapy, namely antitumor nano-immunotherapy has been paid increasing attention. Antitumor nano-immunotherapy is undergoing a transition from simple to complex, from phenotype to mechanism. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
5. Different doses of ovalbumin exposure on dendritic cells determine their genetic/epigenetic regulation and T cell differentiation
- Author
-
Ying Wang, Pei Gao, Jinhui Wang, Yue Zhou, Shan Chen, Seong H. Cho, Wanting Zhu, Jianjun Chen, Junmei Fu, Yang Yuan, Zizhong Yu, Qing Cheng, Yun Zhu, Wenting Yu, Yanjun Wang, and Weijia Kong
- Subjects
Aging ,Ovalbumin ,T-Lymphocytes ,T cells ,Epigenesis, Genetic ,Mice ,Immune system ,Animals ,Epigenetics ,Gene ,signal pathway ,Mice, Inbred BALB C ,biology ,Dose-Response Relationship, Drug ,Antigen processing ,Chemistry ,Cell Differentiation ,Cell Biology ,Dendritic Cells ,DNA Methylation ,allergy ,Coculture Techniques ,Cell biology ,Gene Expression Regulation ,T cell differentiation ,DNA methylation ,biology.protein ,Female ,Signal transduction ,RNA-seq ,Research Paper ,Signal Transduction - Abstract
It has been reported that allergen dosage can impact the differentiation of dendritic cells (DCs)-mediated T cells. However, the mechanisms of such dose-dependent differentiation are poorly understood. In this study, bone marrow-derived immature DCs stimulated with Ovalbumin (OVA) of different concentrations (0, 10, 100, 1000, 10000μg/ml, respectively). DCs were then co-cultured with naive T cells. RNA-sequencing detection and DNA methylation of DCs were performed. We show that when DCs were stimulated with low-dose (10μg/ml), 77 genes were up-regulated and 87 genes down-regulated. Most activated genes were related to ribosome synthesis and ion channel inhibition. At the medium-dose (100μg/ml), 339 genes were up-regulated and 168 genes down-regulated. Most activated genes involved cytokine synthesis and regulation of immune responses. At high-dose (10000μg/ml), 2497 genes were up-regulated and 1156 genes down-regulated. TNF signaling pathway, NF-kappa B signaling pathway, antigen processing and presentation signaling pathway were mostly up-regulated. The related co-stimulators, co-inhibitory molecules, inhibitory cytokines, negative regulating enzymes were highly expressed. The monocarbate, coenzyme, fatty acid, glucolipid, starch, sucrose and other metabolism-related signaling pathways were down-regulated. The profiles of DNA methylation and RNA synthesis of DCs varied with different doses of OVA, which serves to induce T cells to differentiate in various directions.
- Published
- 2020
6. Artificial Mini Dendritic Cells Boost T Cell–Based Immunotherapy for Ovarian Cancer
- Author
-
Yu Li, Jiani Yang, Shanshan Cheng, Zhiyou Yang, Cheng Zhong, Yue Jin, Yu Wang, Jun Ma, Yuan Li, Nan Zhang, Chao Wang, and Cong Xu
- Subjects
General Chemical Engineering ,T cell ,medicine.medical_treatment ,Antigen presentation ,T cells ,General Physics and Astronomy ,Medicine (miscellaneous) ,02 engineering and technology ,010402 general chemistry ,01 natural sciences ,Biochemistry, Genetics and Molecular Biology (miscellaneous) ,Metastasis ,Immune system ,Cancer immunotherapy ,Medicine ,General Materials Science ,dendritic cells ,lcsh:Science ,Full Paper ,business.industry ,General Engineering ,Cancer ,Immunotherapy ,Dendritic cell ,Full Papers ,021001 nanoscience & nanotechnology ,medicine.disease ,0104 chemical sciences ,medicine.anatomical_structure ,ovarian cancer ,Cancer research ,lcsh:Q ,immunotherapy ,0210 nano-technology ,business ,nanovaccines - Abstract
Ovarian cancer is the most lethal gynecological malignancy with high recurrence rates and low survival rates, remaining a disease of high unmet need. Cancer immunotherapy, which harnesses the potential of the immune system to attack tumors, has emerged as one of the most promising treatment options in recent years. As an important form of immunotherapy, dendritic cell (DC)–based vaccines have demonstrated the ability to induce an immune response, while clinical efficacy of DC vaccines remains unsubstantiated as long‐term benefit is only reported in a restricted proportion of patients. Here, a biomimetic nanovaccine derived from DCs is developed through cell membrane coating nanotechnology. This nanovaccine, denoted “mini DC,” inherits the ability of antigen presentation and T cells' stimulation from DCs and is shown to elicit enhanced activation of T cells both in vitro and in vivo. In a mouse model of ovarian cancer, mini DCs exhibit superior therapeutic and prophylactic efficacy against cancer including delayed tumor growth and reduced tumor metastasis compared with DC vaccine. These findings suggest that mini DCs may serve as a facile and potent vaccine to boost anticancer immunotherapy., This work reports a biomimetic nanovaccine derived from dendritic cells (DCs). This nanovaccine possesses abilities of antigen presentation and T cells' stimulation and is shown to elicit enhanced activation of T cells both in vitro and in vivo. It also exhibits superior therapeutic and prophylactic efficacy against tumors compared with DC vaccine in a mouse model of ovarian cancer.
- Published
- 2020
7. A Mathematical Modelling of Initiation of Dendritic Cells-Induced T Cell Immune Response
- Author
-
Wen-Hui Hu, Jinhua Long, Yan Ouyang, Zuquan Hu, Zhu Zeng, Lina Liu, Shichao Zhang, Yuan-Nong Ye, Jing Zhou, Fuzhou Tang, Jin Chen, Yun Wang, Wei Qiu, Wen-Zhu Huang, and Guoqiang Xu
- Subjects
dendritic cell ,T cell ,T-Lymphocytes ,T cells ,chemical and pharmacologic phenomena ,Biology ,Lymphocyte Activation ,Applied Microbiology and Biotechnology ,immune response ,Immune system ,Cell Movement ,medicine ,T cell immunity ,Humans ,Antigens ,Molecular Biology ,Lymph node ,Ecology, Evolution, Behavior and Systematics ,Cell Proliferation ,Inflammation ,Immunity, Cellular ,Cell Biology ,Dendritic cell ,Dendritic Cells ,Models, Theoretical ,Cell biology ,medicine.anatomical_structure ,ordinary differential equations ,Immunotherapy ,Lymph Nodes ,mathematical model ,Developmental Biology ,Research Paper - Abstract
Dendritic cells (DCs) are the most potent specialized antigen-presenting cells as now known, which play a crucial role in initiating and amplifying both the innate and adaptive immune responses. Immunologically, the motilities and T cell activation capabilities of DCs are closely related to the resulting immune responses. However, due to the complexity of the immune system, the dynamic changes in the number of cells during the peripheral tissue (e.g. skin and mucosa) immune response induced by DCs are still poorly understood. Therefore, this study simulated dynamic number changes of DCs and T cells in this process by constructing several ordinary differential equations and setting the initial conditions of the functions and parameters. The results showed that these equations could simulate dynamic numerical changes of DCs and T cells in peripheral tissue and lymph node, which was in accordance with the physiological conditions such as the duration of immune response, the proliferation rates and the motilities of DCs and T cells. This model provided a theoretical reference for studying the immunologic functions of DCs and practical guidance for the clinical DCs-based therapy against immune-related diseases.
- Published
- 2019
8. A comprehensive update on the immunoregulatory mechanisms of <italic>Akkermansia muciniphila</italic>: insights into active ingredients, metabolites, and nutrient-driven modulation.
- Author
-
Mei, Lihua, Wang, Jiaxin, Hao, Yanling, Zeng, Xiangfang, Yang, Ying, Wu, Zhenlong, and Ji, Yun
- Subjects
- *
GUT microbiome , *T cells , *MEMBRANE proteins , *EXTRACELLULAR vesicles , *DENDRITIC cells , *PROBIOTICS , *MUCUS - Abstract
Abstract
Akkermansia muciniphila (A. muciniphila ) has gained recognition as a pioneering probiotic, exhibiting considerable potential to enhance immune conditions across both humans and animals. The health benefits ofA. muciniphila are attributed to its various components, including outer membrane proteins (PilQ and Amuc_1100), secreted proteins (P9 and AmTARS), extracellular vesicles, and metabolites such as SCFAs, ornithine lipids,γ -aminobutyric acid, cobalamin, and inosine. The dynamic control of the mucus layer byA. muciniphila plays a crucial role in regulating intestinal mucosal immunity. Furthermore,A. muciniphila modulates immune function by interacting with macrophages, dendritic cells, T lymphocytes, and Paneth cells. Increasing the abundance ofA. muciniphila in the gut through nutritional strategies represents a safe and effective means to augment immune function. Various polyphenols, oligosaccharides, and polysaccharides have been shown to elevate the levels of this bacterium, thereby contributing to favorable immunoregulatory outcomes. This paper delves into the latest research advancements related to the probiotic mechanisms ofA. muciniphila and provides an overview of the current understanding of how its abundance responds to nutrients. These insights offer a theoretical foundation for the utilization ofA. muciniphila in immunoregulation. [ABSTRACT FROM AUTHOR]- Published
- 2024
- Full Text
- View/download PDF
9. Medicinal herbs Fructus corni and Semen cuscutae suppress allograft rejection via distinct immune mechanisms
- Author
-
Chuan Zou, Xusheng Liu, Feifei Qiu, Zhenhua Dai, Huazhen Liu, Yu-Qun Zeng, Zi-Ren Su, Yong-Zhuo Liang, Xiao-Wei Jin, and Chun-Lin Liang
- Subjects
Graft Rejection ,0301 basic medicine ,medicine.medical_treatment ,T cells ,Semen ,Traditional Chinese medicine ,030230 surgery ,Real-Time Polymerase Chain Reaction ,T-Lymphocytes, Regulatory ,Mice ,03 medical and health sciences ,Cornus ,0302 clinical medicine ,Immune system ,herbs and transplantation ,Immunity ,Gene expression ,Animals ,Humans ,Transplantation, Homologous ,Medicine ,Immune response ,Medicine, Chinese Traditional ,Immunosuppression Therapy ,Mice, Inbred BALB C ,immunosuppression ,business.industry ,Graft Survival ,Research Paper: Immunology ,FOXP3 ,Drug Synergism ,Forkhead Transcription Factors ,Immunosuppression ,Dendritic Cells ,Skin Transplantation ,Allografts ,Interleukin-12 ,Mice, Inbred C57BL ,030104 developmental biology ,Oncology ,Immunology ,Immunology and Microbiology Section ,Drug Therapy, Combination ,business ,Immunosuppressive Agents ,Intracellular ,Drugs, Chinese Herbal - Abstract
Achieving long-term allograft survival without continuous global immunosuppression is highly desirable because constant immunosuppression causes severe side effects. Traditional Chinese medicine (TCM) has been utilized to treat numerous diseases for centuries. To seek novel immunosuppressive agents, we investigated several Chinese herbal formulas that have been shown to be effective in treating autoimmune diseases. C57BL/6 mice were transplanted with a skin graft from Balb/C donors and treated orally with the TCM. IL-12-expressing dendritic cells and CD4+FoxP3+ Tregs were quantified by flow cytometer while intragraft IL-12 gene expression was measured by real-time PCR. Here we identified a unique TCM, San Si formula, which contains three herbs: Fructus corni (FC), Fructus ligustri lucidi (FLL) and Semen cuscutae (SC). We found that either SC or FC, but not FLL, significantly prolonged skin allograft survival while SC plus FC or San Si formula further delayed allograft rejection compared to SC or FC alone. SC and FC, which did not contain cyclosporine and rapamycin, reduced graft-infiltrating T cells and suppressed their proliferation. Importantly, it was SC, but not FC, that induced CD4+FoxP3+ Tregs in recipients. Tregs induced by SC were also more potent in suppression. In contrast, FC repressed both intracellular IL-12 expression by intragraft DCs and IFNγ expression by graft-infiltrating T cells. Moreover, FC inhibited intragraft IL-12 gene expression. Depleting Tregs and providing exogenous IL-12 completely reversed allograft survival induced by SC plus FC. Thus, SC and FC synergistically suppress allograft rejection via distinct mechanisms.
- Published
- 2016
10. The IDO1 selective inhibitor epacadostat enhances dendritic cell immunogenicity and lytic ability of tumor antigen-specific T cells
- Author
-
Young-Seung Kim, Martin W. Brechbiel, Kwong Y. Tsang, Anna R. Kwilas, Massimo Fantini, Ravi A. Madan, James L. Gulley, Caroline Jochems, Christopher R. Heery, Robert C. Newton, Italia Grenga, Lauren M. Lepone, Jeffrey Schlom, Romaine I. Fernando, James W. Hodge, and Renee N. Donahue
- Subjects
Lipopolysaccharides ,Male ,0301 basic medicine ,3-dioxygenase (IDO) ,indoleamine-2 ,Lymphocyte Activation ,0302 clinical medicine ,Oximes ,Cytotoxic T cell ,Medicine ,Kynurenine ,Sulfonamides ,Tryptophan ,hemic and immune systems ,Middle Aged ,Healthy Volunteers ,Tumor antigen ,Phenotype ,Oncology ,030220 oncology & carcinogenesis ,Female ,Tumor necrosis factor alpha ,Research Paper ,Adult ,T cells ,chemical and pharmacologic phenomena ,Tregs ,Cancer Vaccines ,Peripheral blood mononuclear cell ,Interferon-gamma ,Young Adult ,03 medical and health sciences ,Immune system ,Humans ,Indoleamine-Pyrrole 2,3,-Dioxygenase ,dendritic cells ,Aged ,business.industry ,Granulocyte-Macrophage Colony-Stimulating Factor ,Cancer ,Dendritic cell ,medicine.disease ,CTL ,030104 developmental biology ,Immunology ,Leukocytes, Mononuclear ,Peptides ,business ,T-Lymphocytes, Cytotoxic ,IDO inhibitor - Abstract
// Caroline Jochems 1 , Massimo Fantini 1 , Romaine I. Fernando 1 , Anna R. Kwilas 1 , Renee N. Donahue 1 , Lauren M. Lepone 1 , Italia Grenga 1 , Young-Seung Kim 2 , Martin W. Brechbiel 2 , James L. Gulley 3 , Ravi A. Madan 3 , Christopher R. Heery 1 , James W. Hodge 1 , Robert Newton 4 , Jeffrey Schlom 1, * , Kwong Y. Tsang 1, * 1 Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA 2 Radioimmune Inorganic Chemistry Section, Radiation Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA 3 Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA 4 Incyte Corporation, Wilmington, DE, USA * These authors contributed equally to this work Correspondence to: Jeffrey Schlom, email: js141c@nih.gov Keywords: IDO inhibitor, dendritic cells, T cells, indoleamine-2,3-dioxygenase (IDO), Tregs Received: February 29, 2016 Accepted: April 26, 2016 Published: May 12, 2016 ABSTRACT Epacadostat is a novel inhibitor of indoleamine-2,3-dioxygenase-1 (IDO1) that suppresses systemic tryptophan catabolism and is currently being evaluated in ongoing clinical trials. We investigated the effects of epacadostat on (a) human dendritic cells (DCs) with respect to maturation and ability to activate human tumor antigen-specific cytotoxic T-cell (CTL) lines, and subsequent T-cell lysis of tumor cells, (b) human regulatory T cells (Tregs), and (c) human peripheral blood mononuclear cells (PBMCs) in vitro . Simultaneous treatment with epacadostat and IFN-γ plus lipopolysaccharide (LPS) did not change the phenotype of matured human DCs, and as expected decreased the tryptophan breakdown and kynurenine production. Peptide-specific T-cell lines stimulated with DCs pulsed with peptide produced significantly more IFN-γ, TNFα, GM-CSF and IL-8 if the DCs were treated with epacadostat. These T cells also displayed higher levels of tumor cell lysis on a per cell basis. Epacadostat also significantly decreased Treg proliferation induced by IDO production from IFN-γ plus LPS matured human DCs, although the Treg phenotype did not change. Multicolor flow cytometry was performed on human PBMCs treated with epacadostat; analysis of 123 discrete immune cell subsets revealed no changes in major immune cell types, an increase in activated CD83 + conventional DCs, and a decrease in immature activated Tim3 + NK cells. These studies show for the first time several effects of epacadostat on human DCs, and subsequent effects on CTL and Tregs, and provide a rationale as to how epacadostat could potentially increase the efficacy of immunotherapeutics, including cancer vaccines.
- Published
- 2016
11. A comparison of the International Consensus and 5th WHO classifications of T‐cell lymphomas and histiocytic/dendritic cell tumours.
- Author
-
Falini, Brunangelo, Lazzi, Stefano, and Pileri, Stefano
- Subjects
DENDRITIC cells ,T cells ,LYMPHOMAS ,TUMORS ,CLASSIFICATION ,RETICULUM cell sarcoma - Abstract
Summary: Since the publication in 2017 of the revised 4th Edition of the World Health Organization (WHO) classification of haematolymphoid tumours, here referred to as WHO‐HAEM4, significant clinicopathological, immunophenotypic and molecular advances have been made in the field of lymphomas, contributing to refining the diagnostic criteria of several diseases, upgrading entities previously defined as provisional and identifying new entities. This process has resulted in two recent classification proposals of lymphoid neoplasms: the International Consensus Classification (ICC) and the 5th edition of the WHO classification (WHO‐HAEM5). In this paper, we review and compare the two classifications in terms of diagnostic criteria and entity definition, focusing on T‐cell lymphomas and histiocytic/dendritic cell tumours. Moreover, we update the genetic data of the various pathological entities. The main goal is to provide a tool to facilitate the work of the pathologists, haematologists and researchers involved in the diagnosis and treatment of these haematological malignancies. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
12. BIFURCATION ANALYSIS IN A TUMOR-IMMUNE SYSTEM INTERACTION MODEL WITH DENDRITIC CELL THERAPY AND IMMUNE RESPONSE DELAY.
- Author
-
YUYUE ZHANG, LIQI XIE, YUEPING DONG, JICAI HUANG, SHIGUI RUAN, and YASUHIRO TAKEUCHI
- Subjects
CELLULAR therapy ,IMMUNE response ,HOPF bifurcations ,T cells ,DENDRITIC cells ,ACTIVATION energy ,HOPFIELD networks - Abstract
In this paper, we study a tumor-immune system interaction model with dendritic cell therapy and immune response delay. First, it is shown that the ODE version of the model has a Bogdanov--Takens (BT) singularity or a weak focus with multiplicity at most 1 for different parameter values. As the parameters vary, the ODE model undergoes supercritical Hopf bifurcation and supercritical BT bifurcation. Our analysis indicates that there exists a threshold value of the activation rate of T cells, below which tumor immune escape occurs, above or at which T cells and tumor cells coexist in the form of a stable periodic oscillation or steady state. Second, we study how the immune response delay affects the dynamics of the model. Our results reveal that the delay can destabilize the stable positive equilibrium through Hopf bifurcation. Furthermore, the direction and stability of Hopf bifurcation are derived. When there is a cusp, we show that it is a BT singularity for any delay and the delay model also undergoes BT bifurcation. Finally, numerical simulations are presented to illustrate the theoretical results. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
13. Induction of innate immune signatures following polyepitope protein-glycoprotein B-TLR4&9 agonist immunization generates multifunctional CMV-specific cellular and humoral immunity
- Author
-
Vijayendra Dasari, Andrea Schuessler, Rajiv Khanna, Jie Zhong, and Corey Smith
- Subjects
Human cytomegalovirus ,animal diseases ,CD8-Positive T-Lymphocytes ,Antibodies, Viral ,Cytomegalovirus Vaccines ,Epitopes ,Viral Envelope Proteins ,vaccine ,antibody ,cytokine ,Immunology and Allergy ,innate immunity ,epitope ,Vaccines, Synthetic ,Toll-like receptor ,biology ,virus diseases ,Acquired immune system ,Vaccines, Subunit ,Antibody ,Research Paper ,medicine.drug ,protein antigen ,Recombinant Fusion Proteins ,Immunology ,T cells ,Mice, Transgenic ,chemical and pharmacologic phenomena ,Adjuvants, Immunologic ,Immunity ,medicine ,Animals ,dendritic cells ,cytomegalovirus ,Pharmacology ,Innate immune system ,biochemical phenomena, metabolism, and nutrition ,medicine.disease ,Antibodies, Neutralizing ,Virology ,Toll-Like Receptor 4 ,Toll-Like Receptor 9 ,Humoral immunity ,biology.protein ,toll-like receptor ,bacteria ,Immunization ,Lymph Nodes ,Cytomegalovirus vaccine - Abstract
Recent studies have suggested that a successful subunit human cytomegalovirus (CMV) vaccine requires improved formulation to generate broad-based anti-viral immunity following immunization. Here we report the development of a non-live protein-based vaccine strategy for CMV based on a polyepitope protein and CMV glycoprotein B (gB) adjuvanted with TLR4 and/or TLR9 agonists. The polyepitope protein includes contiguous multiple MHC class I-restricted epitopes with an aim to induce CD8(+) T cell immunity, while gB is an important target for CD4(+) T cell immunity and neutralizing antibodies. Optimal immunogenicity of this bivalent non-live protein vaccine formulation was dependent upon the co-administration of both the TLR4 and TLR9 agonist, which was associated with the activation of innate immune signatures and the influx of different DC subsets including plasmacytoid DCs and migratory CD8-DEC205+CD103-CD326- langerin-negative dermal DCs into the draining lymph nodes. Furthermore these professional antigen presenting cells also expressed IL-6, IL-12p70, TNFα, and IFNα which play a crucial role in the activation of adaptive immunity. In summary, this study provides a novel platform technology in which broad-based anti-CMV immune responses upon vaccination can be maximised by co-delivery of viral antigens and TLR4 and 9 agonists which induce activation of innate immune signatures and promote potent antigen acquisition and cross-presentation by multiple DC subsets.
- Published
- 2014
14. What Is Currently Known about the Role of CXCL10 in SARS-CoV-2 Infection?
- Author
-
Gudowska-Sawczuk, Monika and Mroczko, Barbara
- Subjects
CHEMOKINES ,COVID-19 ,SARS-CoV-2 ,T cells ,KILLER cells ,CHEMOKINE receptors ,CYTOKINE release syndrome ,DENDRITIC cells - Abstract
Dysregulation of the immune response plays an important role in the progression of SARS-CoV-2 infection. A "cytokine storm", which is a phenomenon associated with uncontrolled production of large amounts of cytokines, very often affects patients with COVID-19. Elevated activity of chemotactic cytokines, called chemokines, can lead to serious consequences. CXCL10 has an ability to activate its receptor CXCR3, predominantly expressed on macrophages, T lymphocytes, dendritic cells, natural killer cells, and B cells. So, it has been suggested that the chemokine CXCL10, through CXCR3, is associated with inflammatory diseases and may be involved in the development of COVID-19. Therefore, in this review paper, we focus on the role of CXCL10 overactivity in the pathogenesis of COVID-19. We performed an extensive literature search for our investigation using the MEDLINE/PubMed database. Increased concentrations of CXCL10 were observed in COVID-19. Elevated levels of CXCL10 were reported to be associated with a severe course and disease progression. Published studies revealed that CXCL10 may be a very good predictive biomarker of patient outcome in COVID-19, and that markedly elevated CXCL10 levels are connected with ARDS and neurological complications. It has been observed that an effective treatment for SARS-CoV-2 leads to inhibition of "cytokine storm", as well as reduction of CXCL10 concentrations. It seems that modulation of the CXCL10–CXCR3 axis may be an effective therapeutic target of COVID-19. This review describes the potential role of CXCL10 in the pathogenesis of COVID-19, as well as its potential immune–therapeutic significance. However, future studies should aim to confirm the prognostic, clinical, and therapeutic role of CXCL10 in SARS-CoV-2 infection. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
15. The Role of Traditional Chinese Medicine in Cancer Immunotherapy: Current Status and Future Directions.
- Author
-
Xie, Jinxin, Huang, Huiming, Li, Xingxing, Ouyang, Lishan, Wang, Longyan, Liu, Dongxiao, Wei, Xuejiao, Tan, Peng, Tu, Pengfei, and Hu, Zhongdong
- Subjects
DENDRITIC cells ,INTERLEUKINS ,CYTOKINES ,HERBAL medicine ,IMMUNE checkpoint proteins ,FIBROBLASTS ,DRUG-herb interactions ,CARCINOGENESIS ,IMMUNOSUPPRESSION ,KILLER cells ,MACROPHAGES ,TUMORS ,T cells ,IMMUNOTHERAPY ,CHINESE medicine ,THERAPEUTICS - Abstract
The tumor microenvironment (TME) plays an important role in the development of tumors. Immunoregulatory cells and cytokines facilitate cancer cells to avoid immune surveillance. Overexpression of immune checkpoint molecules such as CTLA-4 and PD-1/PD-L1 inhibits immune function and enables cancer cells to avoid clearance by the immune system. Thus, minimizing tumor immunosuppression could be an important strategy for cancer therapy. Currently, many immune checkpoint-targeted drugs, such as PD-1/PD-L1 inhibitors, have been approved for marketing and have shown unique advantages in the clinical treatment of cancers. The concept of "strengthening resistance to eliminate pathogenic factors" in traditional Chinese medicine (TCM) is consistent with the immunotherapy of cancer. According to previous studies, the role of TCM in tumor immunotherapy is mainly associated with the positive regulation of natural killer cells, CD8/CD4 T cells, dendritic cells, M2 macrophages, interleukin-2, tumor necrosis factor- α , and IFN- γ , as well as with the negative regulation of Tregs, myeloid-derived suppressor cells, cancer-associated fibroblasts, PD-1/PD-L1, transforming growth factor- β , and tumor necrosis factor- β. This paper summarizes the current research on the effect of TCM targeting the TME, and further introduces the research progress on studying the effects of TCM on immune checkpoints. Modern pharmacological studies have demonstrated that TCM can directly or indirectly affect the TME by inhibiting the overexpression of immune checkpoint molecules and enhancing the efficacy of tumor immunotherapy. TCM with immunomodulatory stimulation could be the key factor to achieve benefits from immunotherapy for patients with non-inflammatory, or "cold", tumors. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
16. Human dendritic cells adenovirally-engineered to express three defined tumor antigens promote broad adaptive and innate immunity
- Author
-
Jennifer C. Landsberg, Lisa H. Butterfield, Lazar Vujanovic, LeeAnn T. Blalock, John M. Kirkwood, Jian Shi, Michelle N. Messmer, Angela D. Pardee, and Ronald E. Haskell
- Subjects
T cell ,Immunology ,T cells ,Dendritic cell ,adenovirus ,Biology ,Acquired immune system ,3. Good health ,Cell biology ,tumor immunity ,Interleukin 21 ,medicine.anatomical_structure ,Oncology ,Antigen ,medicine ,melanoma ,Immunology and Allergy ,Cytotoxic T cell ,IL-2 receptor ,dendritic cells ,Antigen-presenting cell ,cancer vaccine ,Research Paper - Abstract
Dendritic cell (DC) immunotherapy has shown a promising ability to promote anti-tumor immunity in vitro and in vivo. Many trials have tested single epitopes and single antigens to activate single T cell specificities, and often CD8(+) T cells only. We previously found that determinant spreading and breadth of antitumor immunity correlates with improved clinical response. Therefore, to promote activation and expansion of polyclonal, multiple antigen-specific CD8(+) T cells, as well as provide cognate help from antigen-specific CD4(+) T cells, we have created an adenovirus encoding three full length melanoma tumor antigens (tyrosinase, MART-1 and MAGE-A6, "AdVTMM"). We previously showed that adenovirus (AdV)-mediated antigen engineering of human DC is superior to peptide pulsing for T cell activation, and has positive biological effects on the DC, allowing for efficient activation of not only antigen-specific CD8(+) and CD4(+) T cells, but also NK cells. Here we describe the cloning and testing of "AdVTMM2," an E1/E3-deleted AdV encoding the three melanoma antigens. This novel three-antigen virus expresses mRNA and protein for all antigens, and AdVTMM-transduced DC activate both CD8(+) and CD4(+) T cells which recognize melanoma tumor cells more efficiently than single antigen AdV. Addition of physiological levels of interferon-α (IFNα) further amplifies melanoma antigen-specific T cell activation. NK cells are also activated, and show cytotoxic activity. Vaccination with multi-antigen engineered DC may provide for superior adaptive and innate immunity and ultimately, improved antitumor responses.
- Published
- 2012
17. Therapeutic Implications of UVB Irradiation in Cancer by Enhancing Anti‐Tumor Immunity†.
- Author
-
Hafeez, Bilal Bin, Alvarado, Ed W., and Kim, Dae Joon
- Subjects
PROGRAMMED cell death 1 receptors ,DENDRITIC cells ,TRANSCRIPTION factors ,SKIN cancer ,COLORECTAL cancer ,T cells ,DOSE-response relationship (Radiation) ,IRRADIATION - Abstract
The UVB irradiation is well known for its impact on the development of skin cancer. However, low UVB irradiation plays a protective role against various human diseases including cancer through its effect on tumor suppression. This article summarizes the key findings of the paper by Park et al., which describes a novel molecular mechanism of moderate UVB irradiation in suppressing the growth of melanoma and colorectal cancer. Key observations in this article are that moderate UVB irradiation can enhance tumor immunity by (1) increased infiltration of CD4+ and CD8+ T cells; (2) increased infiltration of CD103+ conventional type 1 dendritic cells (cDC1); and (3) a significant decrease of M2 tumor associate macrophages (TAMs) into the tumor. The authors further identified the role of Batf3 transcription factor in moderate UVB irradiation‐mediated anti‐tumor immune response. Deletion of Batf3 transcription factor reversed the tumor suppressive effect with decreased CD103+ cDC1 cell infiltration. This pre‐clinical study provides a very novel mechanistic insight into the utilization of moderate UVB irradiation for the management of melanoma and colorectal cancer. This study further provides the direction of new future research to explore moderate UVB irradiation in combination with checkpoint blockade antibodies to enhance immunotherapeutic response against various solid tumors. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
18. Traditional Chinese Medicine for Cancer Treatment.
- Author
-
Liu, Yangli, Fang, Cheng, Luo, Jiaojiao, Gong, Chenyuan, Wang, Lixin, and Zhu, Shiguo
- Subjects
- *
THERAPEUTIC use of antineoplastic agents , *CHINESE medicine , *VASCULAR endothelial growth factors , *TELOMERASE , *MACROPHAGES , *KILLER cells , *T cells , *CANCER patient medical care , *CELL proliferation , *APOPTOSIS , *MYELOID-derived suppressor cells , *METASTASIS , *CELL lines , *ENERGY metabolism , *TUMORS , *CARCINOGENESIS , *GENETIC mutation , *PATHOLOGIC neovascularization , *NATURAL immunity , *DENDRITIC cells , *B cells - Abstract
In recent years, due to advancements in medical conditions and the development of scientific research, the fundamental research of TCM antitumor treatments has progressed from the cellular level to the molecular and genetic levels. Previous studies have demonstrated the significant role of traditional Chinese medicine (TCM) in antitumor therapy through various mechanisms and pathways. Its mechanism of action is closely associated with cancer biology across different stages. This includes inhibiting tumor cell proliferation, blocking invasion and metastasis to surrounding tissues, inducing tumor cell apoptosis, inhibiting tumor angiogenesis, regulating immune function, maintaining genome stability, preventing mutation, and regulating cell energy metabolism. The use of TCM for eliciting antitumor effects not only has a good therapeutic effect and low side effects, it also provides a solid theoretical basis for clinical treatment and medication. This paper reviews the mechanism of the antitumor effects of TCM based on tumor characteristics. Through our review, we found that TCM not only directly inhibits tumors, but also enhances the body's immunity, thereby indirectly inducing an antitumor effect. This function aligns with the TCM theory of "strengthening the body's resistance to eliminate pathogenic factors". Furthermore, TCM will play a significant role in tumor treatment in clinical settings. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
19. Mathematical analysis of Hepatitis C Virus infection model in the framework of non-local and non-singular kernel fractional derivative.
- Author
-
Slimane, Ibrahim, Nazir, Ghazala, Nieto, Juan J., and Yaqoob, Faheem
- Subjects
HEPATITIS C ,CYTOTOXIC T cells ,MATHEMATICAL analysis ,HEPATITIS C virus ,T cells ,DENDRITIC cells - Abstract
In this paper, we study a mathematical model of Hepatitis C Virus (HCV) infection. We present a compartmental mathematical model involving healthy hepatocytes, infected hepatocytes, non-activated dendritic cells, activated dendritic cells and cytotoxic T lymphocytes. The derivative used is of non-local fractional order and with non-singular kernel. The existence and uniqueness of the system is proven and its stability is analyzed. Then, by applying the Laplace Adomian decomposition method for the fractional derivative, we present the semi-analytical solution of the model. Finally, some numerical simulations are performed for concrete values of the parameters and several graphs are plotted to reveal the qualitative properties of the solutions. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
20. Inefficient boosting of antitumor CD8(+) T cells by dendritic-cell vaccines is rescued by restricting T-cell cytotoxic functions
- Author
-
Wafik S. El-Deiry, Joel Zhi-Iong Ma, Jianping Yang, Rachel Perret, Franca Ronchese, Jim S. Qin, Niklas Finnberg, and Antonia Richter
- Subjects
Adoptive cell transfer ,medicine.medical_treatment ,T cell ,Immunology ,T cells ,chemical and pharmacologic phenomena ,tumor immunotherapy ,Immune system ,medicine ,Immunology and Allergy ,Cytotoxic T cell ,dendritic cells ,perforin ,biology ,business.industry ,rodent ,hemic and immune systems ,Dendritic cell ,Immunotherapy ,medicine.anatomical_structure ,Oncology ,Perforin ,biology.protein ,cytotoxicity ,business ,CD8 ,Research Paper - Abstract
Dendritic cells (DCs) are powerful activators of primary and secondary immune responses and have promising activity as anticancer vaccines. However, various populations of immune cells, including natural killer cells, regulatory T cells and especially cytotoxic T lymphocytes (CTLs), can inhibit DC function through cytotoxic clearance. Spontaneous tumor-specific CTL responses are frequently observed in patients before immunotherapy, and it is unclear how such pre-existing responses may affect DC vaccines. We used an adoptive transfer model to show that DC vaccination fail to induce the expansion of pre-existing CTLs or increase their production of interferon γ (IFNγ). The expansion and effector differentiation of naive host CD8(+) T cells was also suppressed in the presence of CTLs of the same specificity. Suppression was caused by the cytotoxic functions of the adoptively transferred CTLs, as perforin-deficient CTLs could respond to DC vaccination by expanding and increasing IFNγ production. Proliferation and effector differentiation of host CD8(+) T cells as well as resistance to tumor challenge were also significantly increased. Expression of perforin by antitumor CTLs was critical in regulating the survival of vaccine DCs, while FAS/FASL and TRAIL/DR5 had a significant, but comparatively smaller, effect. We conclude that perforin-expressing CTLs can suppress the activity of DC-based vaccines and prevent the expansion of naive and memory CD8(+) T cells as well as antitumor immune responses. We suggest that, paradoxically, temporarily blocking the cytotoxic functions of CTLs at the time of DC vaccination should result in improved vaccine efficiency and enhanced antitumor immunity.
- Published
- 2012
21. Forthcoming papers.
- Subjects
LISTS ,DNA ,DENDRITIC cells ,T cells ,ANTINEOPLASTIC agents ,IMMUNOLOGY - Abstract
The article presents a list of forthcoming research papers related to immunology. They include "DNA and its cationic lipid complexes induce CpG motif-dependent activation of murine dendritic cells," "Mature dendritic cells pulsed with exosomes stimulate efficient cytotoxic T lymphocyte responses and antitumor immunity," and "Involvement of IL-10 in exhaustion of myeloid dendritic cells and rescue by CD40 stimulation."
- Published
- 2006
- Full Text
- View/download PDF
22. On the possibility of oscillating in the Ebola virus dynamics and investigating the effect of the lifetime of T lymphocytes.
- Author
-
Ghaemi, Mehrdad, Shojafar, Mina, Zabihinpour, Zahra, and Asgari, Yazdan
- Subjects
EBOLA virus ,CELL motility ,T cells ,CELLULAR automata ,DENDRITIC cells ,OSCILLATIONS - Abstract
Ebola virus (EBOV) targets immune cells and tries to inactivate dendritic cells and interferon molecules to continue its replication process. Since EBOV detailed mechanism has not been identified so far, it would be useful to understand the growth and spread of EBOV dynamics based on mathematical methods and simulation approaches. Computational approaches such as Cellular Automata (CA) have the advantage of simplicity over solving complicated differential equations. The spread of Ebola virus in lymph nodes is studied using a simplified Cellular Automata model with only four parameters. In addition to considering healthy and infected cells, this paper also considers T lymphocytes as well as cell movement ability during the simulation in order to investigate different scenarios in the dynamics of an EBOV system. It is shown that the value of the probability of death of T cells affects the number of infected cells significantly in the steady-state. For a special case of parameters set, the system shows oscillating dynamics. The results were in good agreement with an ordinary differential equation-based model which indicated CA method in combination with experimental discoveries could help biologists find out more about the EBOV mechanism and hopefully to control the disease. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
23. An immune optimization based deterministic dendritic cell algorithm.
- Author
-
Zhou, Wen and Liang, Yiwen
- Subjects
DENDRITIC cells ,ALGORITHMS ,T cells ,IMMUNE system - Abstract
Anomaly detection is an important issue, which has been deeply studied in different research domains and application fields. The dendritic cell algorithm (DCA) is one of the most popular artificial immune system inspired approaches to handle anomaly detection problems. The performance of DCA depends significantly on the parameters used to compute the relationship between input instance and detectors. However, we find that while the DCA's performance is good in practical applications, it is difficult to analyze due to the empirical based parameters and lacks adaptability. This paper studies how to effectively learn appropriate parameters for deterministic DCA (dDCA) for anomaly detection tasks. In particular, we propose a novel immune optimization based dDCA (IO-dDCA) for anomaly detection. It consists of dDCA classification, T cell (TC) classification, gradient descent optimization and immune nonlinear dynamic optimization. First, the dDCA is regarded as a binary classifier, and the data instances which are labeled as normal will be classified by a T cell inspired classification method, so as to improve the classification performance of dDCA. Then, to improve dDCA's adaptability, gradient descent is adopted for dDCA parameters' optimization. Finally, the immune nonlinear model is introduced to adjust learning rate in gradient descent to find the optimal parameters. The theoretical and experimental performance analysis of IO-dDCA show effectiveness of the novel approach through simulations, and the experimental results show that the proposed IO-dDCA has good classification accuracy. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
24. Research Advances and Application Prospect of Low-Temperature Plasma in Tumor Immunotherapy.
- Author
-
Wang, Xiangni, Shi, Xingmin, and Zhang, Guanjun
- Subjects
CYTOTOXIC T cells ,DENDRITIC cells ,IMMUNOTHERAPY ,T cells ,TUMORS ,ORAL medicine ,HEALING - Abstract
As an emerging technology, low-temperature plasma (LTP) is widely used in medical fields such as sterilization, wound healing, stomatology, and cancer treatment. Great achievements have been made in tumor therapy. In vitro and in vivo studies have shown that LTP has anti-tumor effects, and LTP is selective to tumor cells. Studies in recent years have found that LTP can activate dendritic cells (DC), macrophages, T cells, and other immune cells to achieve anti-tumor effects. This paper reviews the current status of tumor immunotherapy, the application of LTP in antitumor therapy, the activation of antitumor immunity by LTP, the possible mechanism of LTP in antitumor immunity, and meanwhile analyses the prospect of applying LTP in tumor immunotherapy. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
25. Forthcoming papers.
- Subjects
IMMUNOLOGY ,BIBLIOGRAPHY ,DENDRITIC cells ,DEOXYRIBONUCLEOTIDES ,NUCLEOTIDES ,T cells ,LYMPHOCYTES - Abstract
The article presents a list of articles related to immunology. The articles include "Monocyte-Derived Dendritic Cells From Horses Differ From DC of Humans and Mice," by Susanne Mauel, Falko Steinbach and Hanns Ludwig, "Extended Sequence Preferences for Oligodeoxyribonucleotide Activity," by Peter Lenert, Adam Goeken and Robert Ashman, "On the Logic of Positive Selection," by Melvin Cohn, "CTLA-4 Interacts With Stat5 and Inhibits Stat5-Mediated Transcription," by M. Srahna, L. Van Grunsven, J. Remacle and Peter Vandenberghe, and "Peritoneal Macrophages Supress T Cell Activation by Amino Acid Catabolism," by R. Matlack, K. Yeh, L. Rosini, D. Gonzalez, J. Taylor, D. Silberman, A. Pennello and James Riggs.
- Published
- 2006
- Full Text
- View/download PDF
26. FRT - Fondation Rene Touraine.
- Author
-
Sakaguchi, Shimon, Sallusto, Federica, Gebhardt, Thomas, Stingl, Georg, Clark, Rachael A., Santamaria‐Babí, Luis F., Guttman‐Yassky, Emma, Schuler, Gerold, and Koenen, Hans J.
- Subjects
T cells ,DERMATOLOGY conferences ,DERMATOLOGY ,SKIN inflammation ,DENDRITIC cells ,CONFERENCES & conventions - Abstract
The article introduces scientific conference papers on T cells and skin to be presented at the 22nd Scientific meeting 2014 of the Fondation René Touraine (FRT), a European non-governmental organization that promotes therapeutic progress in dermatology, on 5th December 2014 in Paris, France. Papers by researchers Shimon Sakaguchi, Federica Sallusto and Thomas Gebhardt are included. Specific topics include immune abnormalities found in atopic dermatitis and adoptive transfer of dendritic cells.
- Published
- 2014
- Full Text
- View/download PDF
27. Therapeutic Implications of UVB Irradiation in Cancer by Enhancing Anti‐Tumor Immunity†.
- Author
-
Hafeez, Bilal Bin, Alvarado, Ed W., and Kim, Dae Joon
- Subjects
- *
PROGRAMMED cell death 1 receptors , *DENDRITIC cells , *TRANSCRIPTION factors , *SKIN cancer , *COLORECTAL cancer , *T cells , *DOSE-response relationship (Radiation) , *IRRADIATION - Abstract
The UVB irradiation is well known for its impact on the development of skin cancer. However, low UVB irradiation plays a protective role against various human diseases including cancer through its effect on tumor suppression. This article summarizes the key findings of the paper by Park et al., which describes a novel molecular mechanism of moderate UVB irradiation in suppressing the growth of melanoma and colorectal cancer. Key observations in this article are that moderate UVB irradiation can enhance tumor immunity by (1) increased infiltration of CD4+ and CD8+ T cells; (2) increased infiltration of CD103+ conventional type 1 dendritic cells (cDC1); and (3) a significant decrease of M2 tumor associate macrophages (TAMs) into the tumor. The authors further identified the role of Batf3 transcription factor in moderate UVB irradiation‐mediated anti‐tumor immune response. Deletion of Batf3 transcription factor reversed the tumor suppressive effect with decreased CD103+ cDC1 cell infiltration. This pre‐clinical study provides a very novel mechanistic insight into the utilization of moderate UVB irradiation for the management of melanoma and colorectal cancer. This study further provides the direction of new future research to explore moderate UVB irradiation in combination with checkpoint blockade antibodies to enhance immunotherapeutic response against various solid tumors. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
28. Clinical application of immune checkpoints in targeted immunotherapy of prostate cancer.
- Author
-
Jafari, Sevda, Molavi, Ommoleila, Kahroba, Houman, Hejazi, Mohammad Saied, Maleki-Dizaji, Nasrin, Barghi, Siamak, Kiaie, Seyed Hossein, and Jadidi-Niaragh, Farhad
- Subjects
SUPPRESSOR cells ,PROSTATE cancer ,IMMUNOTHERAPY ,CYTOTOXIC T cells ,PROGRAMMED death-ligand 1 ,T cells ,PROGRAMMED cell death 1 receptors ,DENDRITIC cells - Abstract
Immunotherapy is considered as an effective method for cancer treatment owing to the induction of specific and long-lasting anti-cancer effects. Immunotherapeutic strategies have shown significant success in human malignancies, particularly in prostate cancer (PCa), a major global health issue regarding its high metastatic rates. In fact, the first cancer vaccine approved by FDA was Provenge, which has been successfully used for treatment of PCa. Despite the remarkable success of cancer immunotherapy in PCa, many of the developed immunotherapy methods show poor therapeutic outcomes. Immunosuppression in tumor microenvironment (TME) induced by non-functional T cells (CD4
+ and CD8+ ), tolerogenic dendritic cells (DCs), and regulatory T cells, has been reported to be the main obstacle to the effectiveness of anti-tumor immune responses induced by an immunotherapy method. The present review particularly focuses on the latest findings of the immune checkpoints (ICPs), including CTLA-4, PD-1, PD-L1, LAG-3, OX40, B7-H3, 4-1BB, VISTA, TIM-3, and ICOS; these checkpoints are able to have immune modulatory effects on the TME of PCa. This paper further discusses different approaches in ICPs targeting therapy and summarizes the latest advances in the clinical application of ICP-targeted therapy as monotherapy or in combination with other cancer therapy modalities in PCa. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
29. Immune tolerance at the maternal‐placental interface in healthy pregnancy and pre‐eclampsia.
- Author
-
Valencia‐Ortega, Jorge, Saucedo, Renata, Peña‐Cano, María I., Hernández‐Valencia, Marcelino, and Cruz‐Durán, José G.
- Subjects
RISK factors of preeclampsia ,BLASTOCYST ,DENDRITIC cells ,DISEASES ,IMMUNITY ,IMMUNOLOGICAL tolerance ,INFANT mortality ,INFLAMMATION ,KILLER cells ,MACROPHAGES ,PLACENTA ,PREGNANCY complications ,RISK assessment ,T cells ,DISEASE risk factors - Abstract
Aim: The objective of this review is to describe the immunological mechanisms which facilitate maternal tolerance at the maternal‐placental interface, and to discuss how these mechanisms are disrupted in pre‐eclampsia. Methods: A literature review was performed based on the analysis of papers available on PubMed. The most important and relevant studies regarding the immunological mechanisms which facilitate maternal tolerance in healthy pregnancy and pre‐eclampsia are presented in this article. Results: The maternal‐placental interface is the site where the immune tolerance begins and develops. Within the innate immunity, natural killer cells, macrophages and dendritic cells play a pivotal role in tolerance through regulation of inflammation. On the other hand, within the adaptive immunity, the correct increase of regulatory T cells is crucial for ensuring immune tolerance toward placental cells. Disturbances in maternal tolerance can lead to the appearance of pregnancy complications such as pre‐eclampsia, which has a considerable impact on perinatal morbidity and mortality. Conclusion: Our partial knowledge of immunological mechanisms involved in tolerance at the maternal‐placental interface indicates that pre‐eclampsia is characterized by alterations of this maternal immune tolerance, which could represent the origin of the disease. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
30. Role of tumor-derived exosomes mediated immune cell reprograming in cancer.
- Author
-
Liu, Zening, Chen, Zichao, Zhang, Jing, Liu, Junqiu, Li, Baohong, Zhang, Zhenyong, Cai, Meichao, and Zhang, Zhen
- Subjects
- *
EXOSOMES , *T cells , *CANCER cells , *KILLER cells , *DENDRITIC cells , *TUMOR microenvironment - Abstract
• Release of Tumor-derived Exosomes (TDEs) is involved in intercellular information exchange. • Tumor-derived Exosomes (TDEs) can negatively regulate the tumor microenvironment. • Tumor-derived Exosomes (TDEs) inhibit peritumour immune cells and create an immunosuppressive environment. Tumor-derived exosomes (TDEs), as topologies of tumor cells, not only carry biological information from the mother, but also act as messengers for cellular communication. It has been demonstrated that TDEs play a key role in inducing an immunosuppressive tumor microenvironment (TME). They can reprogram immune cells indirectly or directly by delivering inhibitory proteins, cytokines, RNA and other substances. They not only inhibit the maturation and function of dendritic cells (DCs) and natural killer (NK) cells, but also remodel M2 macrophages and inhibit T cell infiltration to promote immunosuppression and create a favorable ecological niche for tumor growth, invasion and metastasis. Based on the specificity of TDEs, targeting TDEs has become a new strategy to monitor tumor progression and enhance treatment efficacy. This paper reviews the intricate molecular mechanisms underlying the immunosuppressive effects induced by TDEs to establish a theoretical foundation for cancer therapy. Additionally, the challenges of TDEs as a novel approach to tumor treatment are discussed. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
31. Dominant immune tolerance in the intestinal tract imposed by RelB-dependent migratory dendritic cells regulates protective type 2 immunity.
- Author
-
Geiselhöringer, Anna-Lena, Kolland, Daphne, Patt, Arisha Johanna, Hammann, Linda, Köhler, Amelie, Kreft, Luisa, Wichmann, Nina, Hils, Miriam, Ruedl, Christiane, Riemann, Marc, Biedermann, Tilo, Anz, David, Diefenbach, Andreas, Voehringer, David, Schmidt-Weber, Carsten B., Straub, Tobias, Pasztoi, Maria, and Ohnmacht, Caspar
- Subjects
REGULATORY T cells ,TRANSCRIPTION factors ,DENDRITIC cells ,INTESTINAL infections ,IMMUNOLOGICAL tolerance ,T cells ,HOMEOSTASIS - Abstract
Dendritic cells (DCs) are crucial for initiating protective immune responses and have also been implicated in the generation and regulation of Foxp3
+ regulatory T cells (Treg cells). Here, we show that in the lamina propria of the small intestine, the alternative NF-κB family member RelB is necessary for the differentiation of cryptopatch and isolated lymphoid follicle-associated DCs (CIA-DCs). Moreover, single-cell RNA sequencing reveals a RelB-dependent signature in migratory DCs in mesenteric lymph nodes favoring DC-Treg cell interaction including elevated expression and release of the chemokine CCL22 from RelB-deficient conventional DCs (cDCs). In line with the key role of CCL22 to facilitate DC-Treg cell interaction, RelB-deficient DCs have a selective advantage to interact with Treg cells in an antigen-specific manner. In addition, DC-specific RelB knockout animals show increased total Foxp3+ Treg cell numbers irrespective of inflammatory status. Consequently, DC-specific RelB knockout animals fail to mount protective Th2-dominated immune responses in the intestine after infection with Heligmosomoides polygyrus bakeri. Thus, RelB expression in cDCs acts as a rheostat to establish a tolerogenic set point that is maintained even during strong type 2 immune conditions and thereby is a key regulator of intestinal homeostasis. Dendritic cells play intricate roles in engaging a range of immune cells. Here, the authors establish a role for the transcription factor RelB in dendritic cells as a molecular rheostat that controls the level of immune tolerance by limiting the number of regulatory T cells. [ABSTRACT FROM AUTHOR]- Published
- 2024
- Full Text
- View/download PDF
32. Single-cell spatiotemporal analysis reveals alveolar dendritic cell–T cell immunity hubs defending against pulmonary infection.
- Author
-
Cong, Boyi, Dong, Xuan, Yang, Zongheng, Yu, Pin, Chai, Yangyang, Liu, Jiaqi, Zhang, Meihan, Zang, Yupeng, Kang, Jingmin, Feng, Yu, Liu, Yi, Feng, Weimin, Wang, Dehe, Deng, Wei, Li, Fengdi, Song, Zhiqi, Wang, Ziqiao, Chen, Xiaosu, Qin, Hua, and Yu, Qinyi
- Subjects
GOLDEN hamster ,DENDRITIC cells ,LUNG infections ,RNA sequencing ,LUNGS ,T cells - Abstract
How immune cells are spatiotemporally coordinated in the lung to effectively monitor, respond to, and resolve infection and inflammation in primed form needs to be fully illustrated. Here we apply immunocartography, a high-resolution technique that integrates spatial and single-cell RNA sequencing (scRNA-seq) through deconvolution and co-localization analyses, to the SARS-CoV-2-infected Syrian hamster model. We generate a comprehensive transcriptome map of the whole process of pulmonary infection from physiological condition, infection initiation, severe pneumonia to natural recovery at organ scale and single-cell resolution, with 142,965 cells and 45 lung lobes from 25 hamsters at 5 time points. Integrative analysis identifies that alveolar dendritic cell–T cell immunity hubs, where Ccr7
+ Ido1+ dendritic cells, Cd160+ Cd8+ T cells, and Tnfrsf4+ Cd4+ T cells physiologically co-localize, rapidly expand during SARS-CoV-2 infection, eliminate SARS-CoV-2 with the aid of Slamf9+ macrophages, and then restore to physiological levels after viral clearance. We verify the presence of these cell subpopulations in the immunity hubs in normal and SARS-CoV-2-infected hACE2 mouse models, as well as in publicly available human scRNA-seq datasets, demonstrating the potential broad relevance of our findings in lung immunity. [ABSTRACT FROM AUTHOR]- Published
- 2024
- Full Text
- View/download PDF
33. Peculiar transcriptional reprogramming with functional impairment of dendritic cells upon exposure to transformed HTLV-1-infected cells.
- Author
-
Carcone, Auriane, Mortreux, Franck, Alais, Sandrine, Mathieu, Cyrille, Journo, Chloé, and Dutartre, Hélène
- Subjects
HTLV-I ,CELL physiology ,DENDRITIC cells ,VIRUS diseases ,CELL communication ,T cells - Abstract
Manipulation of immune cell functions, independently of direct infection of these cells, emerges as a key process in viral pathophysiology. Chronic infection by Human T-cell Leukemia Virus type 1 (HTLV-1) is associated with immune dysfunctions, including misdirected responses of dendritic cells (DCs). Here, we interrogate the ability of transformed HTLV-1-infected T cells to manipulate human DC functions. We show that exposure to transformed HTLV-1-infected T cells induces a biased and peculiar transcriptional signature in monocyte-derived DCs, associated with an inefficient maturation and a poor responsiveness to subsequent stimulation by a TLR4 agonist. This poor responsiveness is also associated with a unique transcriptional landscape characterized by a set of genes whose expression is either conferred, impaired or abolished by HTLV-1 pre-exposure. Induction of this functional impairment requires several hours of coculture with transformed HTLV-1-infected cells, and associated mechanisms driven by viral capture, cell-cell contacts, and soluble mediators. Altogether, this cross-talk between infected T cells and DCs illustrate how HTLV-1 might co-opt communications between cells to induce a unique local tolerogenic immune microenvironment suitable for its own persistence. Author summary: Chronic viral infection is associated with an escape from immune surveillance. This may rely on the induction of inappropriate DC responses, which can contribute to immunopathology. Immune dysfunctions have been repeatedly reported in people living with Human T-cell Leukemia Virus type 1 (HTLV-1), years before fatal clinical symptom onset, including misdirected responses of dendritic cells (DCs). Here, we report that HTLV-1-infected T cells actively manipulate neighboring, uninfected MDDC functions by rewiring their transcriptional response, leading to a biased, pro-tolerogenic responsiveness in MDDCs, induced by the bidirectional release of soluble mediators, in cooperation with mechanisms dependent on cell-cell contacts. This cross-talk illustrate how HTLV-1 might co-opt communications between cells to induce a local tolerogenic immune microenvironment suitable for its own persistence. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
34. Ex Vivo Analysis of the Association of GFP-Expressing L. aethiopica and L. mexicana with Human Peripheral Blood-Derived (PBD) Leukocytes over 24 Hours.
- Author
-
Ranatunga, Medhavi, Deacon, Andrew, Harbige, Laurence S., Dyer, Paul, Boateng, Joshua, and Getti, Giulia T. M.
- Subjects
REGULATORY T cells ,B cells ,FIBROBLASTS ,LEUCOCYTES ,DENDRITIC cells ,T cells - Abstract
Leishmania parasites are transmitted to mammalian hosts through the bite of sandflies. These parasites can infect phagocytic cells (macrophages, dendritic cells, and neutrophils) and non-phagocytic cells (B cells and fibroblasts). In mice models, the disease development or resolution is linked to T cell responses involving inflammatory cytokines and the activation of macrophages with the M1/M2 phenotype. However, this mechanism does not apply to human infection where a more complex immunological response occurs. The understanding of interactions between immune cells during Leishmania infection in humans is still limited, as current infection models focus on individual cell types or late infection using controlled human infection models (CHIMs). This study investigated the early parasite infection in freshly isolated peripheral blood-derived (PBD) leukocytes over 24 h. Flow cytometer analysis is used in immunophenotyping to identify different subpopulations. The study found that among the L. aethiopica
GFP -associated leukocytes, most cells were neutrophils (55.87% ± 0.09 at 4 h) and monocytes (23.50% ± 0.05% at 24 h). B cells were 12.43% ± 0.10% at 24 h. Additionally, 10–20% of GFP+ leukocytes did not belong to the aforementioned cell types, and further investigation revealed their identity as CD4+ T cells. Data not only confirm previous findings of Leishmania infection with PBD leukocytes and association with B cells but also suggest that CD4+ T cells might influence the early-stage of infection. [ABSTRACT FROM AUTHOR]- Published
- 2024
- Full Text
- View/download PDF
35. A simulation of the random and directed motion of dendritic cells in chemokine fields.
- Author
-
Parr, Avery, Anderson, Nicholas R., and Hammer, Daniel A.
- Subjects
DENDRITIC cells ,CHEMOTAXIS ,CHEMOKINE receptors ,CELL receptors ,ANTIGEN presenting cells ,T cells ,MOTION - Abstract
Dendritic cells (DCs) are the most effective professional antigen-presenting cell. They ferry antigen from the extremities to T cells and are essential for the initiation of an adaptive immune response. Despite interest in how DCs respond to chemical stimuli, there have been few attempts to model DC migration. In this paper, we simulate the motility of DCs by modeling the generation of forces by filopodia and a force balance on the cell. The direction of fliopodial extension is coupled to differential occupancy of cognate chemokine receptors across the cell. Our model simulates chemokinesis and chemotaxis in a variety of chemical and mechanical environments. Simulated DCs undergoing chemokinesis were measured to have a speed of 5.1 ± 0.07 μm·min
-1 and a persistence time of 3.2 ± 0.46 min, consistent with experiment. Cells undergoing chemotaxis exhibited a stronger chemotactic response when exposed to lower average chemokine concentrations, also consistent with experiment. We predicted that when placed in two opposing gradients, cells will cluster in a line, which we call the “line of equistimulation;” this clustering has also been observed. We calculated the effect of varying gradient steepness on the line of equistimulation, with steeper gradients resulting in tighter clustering. Moreover, gradients are found to be most potent when cells are in a gradient of chemokine whose mean concentration is close to the binding of the Kd to the receptor, and least potent when the mean concentration is 0.1Kd . Comparing our simulations to experiment, we can give a quantitative measure of the strength of certain chemokines relative to others. Assigning the signal of CCL19 binding CCR7 a baseline strength of 1, we found CCL21 binding CCR7 had a strength of 0.28, and CXCL12 binding CXCR4 had a strength of 0.30. These differences emerge despite both chemokines having virtually the same Kd , suggesting a mechanism of signal amplification in DCs requiring further study. [ABSTRACT FROM AUTHOR]- Published
- 2019
- Full Text
- View/download PDF
36. Delivery of self-amplifying RNA vaccines in in vitro reconstituted virus-like particles.
- Author
-
Biddlecome, Adam, Habte, Habtom H., McGrath, Katherine M., Sambanthamoorthy, Sharmila, Wurm, Melanie, Sykora, Martina M., Knobler, Charles M., Lorenz, Ivo C., Lasaro, Marcio, Elbers, Knut, and Gelbart, William M.
- Subjects
DENDRITIC cells ,RNA replicase ,VIRUS-like particles ,RNA ,PLANT viruses ,INSECT viruses - Abstract
Many mRNA-based vaccines have been investigated for their specific potential to activate dendritic cells (DCs), the highly-specialized antigen-presenting cells of the immune system that play a key role in inducing effective CD4
+ and CD8+ T-cell responses. In this paper we report a new vaccine/gene delivery platform that demonstrates the benefits of using a self-amplifying (“replicon”) mRNA that is protected in a viral-protein capsid. Purified capsid protein from the plant virus Cowpea Chlorotic Mottle Virus (CCMV) is used to in vitro assemble monodisperse virus-like particles (VLPs) containing reporter proteins (e.g., Luciferase or eYFP) or the tandem-repeat model antigen SIINFEKL in RNA gene form, coupled to the RNA-dependent RNA polymerase from the Nodamura insect virus. Incubation of immature DCs with these VLPs results in increased activation of maturation markers – CD80, CD86 and MHC-II – and enhanced RNA replication levels, relative to incubation with unpackaged replicon mRNA. Higher RNA uptake/replication and enhanced DC activation were detected in a dose-dependent manner when the CCMV-VLPs were pre-incubated with anti-CCMV antibodies. In all experiments the expression of maturation markers correlates with the RNA levels of the DCs. Overall, these studies demonstrate that: VLP protection enhances mRNA uptake by DCs; coupling replicons to the gene of interest increases RNA and protein levels in the cell; and the presence of anti-VLP antibodies enhances mRNA levels and activation of DCs in vitro. Finally, preliminary in vivo experiments involving mouse vaccinations with SIINFEKL-replicon VLPs indicate a small but significant increase in antigen-specific T cells that are doubly positive for IFN and TFN induction. [ABSTRACT FROM AUTHOR]- Published
- 2019
- Full Text
- View/download PDF
37. Combination therapy for cancer with oncolytic virus and checkpoint inhibitor: A mathematical model.
- Author
-
Friedman, Avner and Lai, Xiulan
- Subjects
CANCER cells ,CANCER treatment ,IMMUNE response ,MATHEMATICAL models ,COMBINATION drug therapy - Abstract
Oncolytic virus (OV) is a replication competent virus that selectively invades cancer cells; as these cells die under the viral burden, the released virus particles proceed to infect other cancer cells. Oncolytic viruses are designed to also be able to stimulate the anticancer immune response. Thus, one may represent an OV by two parameters: its replication potential and its immunogenicity. In this paper we consider a combination therapy with OV and a checkpoint inhibitor, anti-PD-1. We evaluate the efficacy of the combination therapy in terms of the tumor volume at some later time, for example, 6 months from initial treatment. Since T cells kill not only virus-free cancer cells but also virus-infected cancer cells, the following question arises: Does increasing the amount of the checkpoint inhibitor always improve the efficacy? We address this question, by a mathematical model consisting of a system of partial differential equations. We use the model to construct, by simulations, an efficacy map in terms of the doses of the checkpoint inhibitor and the OV injection. We show that there are regions in the map where an increase in the checkpoint inhibitor actually decreases the efficacy of the treatment. We also construct efficacy maps with checkpoint inhibitor vs. the replication potential of the virus that show the same antagonism, namely, an increase in the checkpoint inhibitor may actually decrease the efficacy. These results have implications for clinical trials. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
38. Forced expression of IL-7R promotes CD8 T cell cytotoxicity to self antigen.
- Author
-
Peng, YuFeng
- Subjects
INTERLEUKIN-7 receptors ,CYTOTOXIC T cells ,CD8 antigen ,PROTEIN expression ,DENDRITIC cells - Abstract
Cross-presentation of apoptotic cell associated antigens by immature dendritic cells prevents the activation of self reactive CD8 T cells. Tolerized self reactive CD8 T cells down-regulate IL-7R expression on their surface. Whether over-expression of IL-7R can reverse their fate and function has not been examined. In this paper, we showed forced expression of IL-7R in OT-I T cells by a transgene enhanced CD8 T cell mediated diabetes in the RIP-mOVA model. Although IL-7R Tg (transgenic) did not completely reverse the deletion of OT-I T cells, it provided a significant survival advantage over w.t OT-I T cells. Furthermore, IL7R Tg OT-I T cells isolated from diabetic pancreata displayed increased production of IFN-γ, higher expression of T-bet, and increased externalization of CD107a. We also found that immature DCs containing apoptotic cells expressed high levels of PDL-1 on their surface. Although IL-7R Tg did not change PD1 expression on activated OT-I cells in vivo, the transgene enabled a significantly lower number of OT-I T cells to induce diabetes in the absence of PDL-1. Our results demonstrated that forced expression of IL-7R not only improved the functionality of tolerized CD8 T cells, it also acted in synergy with PDL-1 deficiency to further promote CD8 T cell cytotoxicity to self antigens. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
39. A minimally invasive optical trapping system to understand cellular interactions at onset of an immune response.
- Author
-
Glass, David G., McAlinden, Niall, Millington, Owain R., and Wright, Amanda J.
- Subjects
IMMUNE response ,CELL communication ,T cells ,ANTIGENS ,DENDRITIC cells - Abstract
T-cells and antigen presenting cells are an essential part of the adaptive immune response system and how they interact is crucial in how the body effectively fights infection or responds to vaccines. Much of the experimental work studying interaction forces between cells has looked at the average properties of bulk samples of cells or applied microscopy to image the dynamic contact between these cells. In this paper we present a novel optical trapping technique for interrogating the force of this interaction and measuring relative interaction forces at the single-cell level. A triple-spot optical trap is used to directly manipulate the cells of interest without introducing foreign bodies such as beads to the system. The optical trap is used to directly control the initiation of cell-cell contact and, subsequently to terminate the interaction at a defined time point. The laser beam power required to separate immune cell pairs is determined and correlates with the force applied by the optical trap. As proof of concept, the antigen-specific increase in interaction force between a dendritic cell and a specific T-cell is demonstrated. Furthermore, it is demonstrated that this interaction force is completely abrogated when T-cell signalling is blocked. As a result the potential of using optical trapping to interrogate cellular interactions at the single cell level without the need to introduce foreign bodies such as beads is clearly demonstrated. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
40. The Effects of Gynecological Tumor Irradiation on the Immune System.
- Author
-
Romero Fernandez, Jesus, Cordoba Largo, Sofia, Benlloch Rodriguez, Raquel, and Gil Haro, Beatriz
- Subjects
T cells ,MACROPHAGES ,APOPTOSIS ,IMMUNE system ,ENDOTHELIUM ,FEMALE reproductive organ tumors ,RADIOBIOLOGY ,CYTOKINES ,IMMUNOSUPPRESSION ,DENDRITIC cells - Abstract
Simple Summary: Radiobiology has evolved from a mechanistic model based on DNA damage, and other response factors, into a more complex model including effects on the immune system and the tumor microenvironment (TME). Irradiation has an immunomodulatory effect that can manifest as increased anti-tumor immunity or immunosuppression. Irradiation promotes anti-tumor immunity through pro-inflammatory cytokines and endothelial damage, the recruitment of immune cells, and radiation-induced immunogenic cell death (ICD), characterized by the release of damage-associated molecular patterns (DAMPs) and tumor antigens. Irradiation activates both the innate and adaptive arms of the immune system. Irradiation also produces immunosuppression via the recruitment and activation of immune cells, with immunosuppressive effects. In this work, we discuss the mechanism involved in radiation-induced immune effects on which the combination of radiotherapy and immunotherapy for gynecological cancers is based. Radiobiology has evolved from a mechanistic model based on DNA damage and response factors into a more complex model that includes effects on the immune system and the tumor microenvironment (TME). Irradiation has an immunomodulatory effect that can manifest as increased anti-tumor immunity or immunosuppression. Irradiation promotes an inflammatory microenvironment through the release of pro-inflammatory cytokines and endothelial damage, which recruit immune system cells to the irradiated area. Radiation-induced immunogenic cell death (ICD), characterized by the release of damage-associated molecular patterns (DAMPs) and tumor antigens, triggers an anti-tumor immune response of both innate and adaptive immunity. Anti-tumor immunity can manifest at a distance from the irradiated area, a phenomenon known as the abscopal effect (AE), which involves dendritic cells and CD8+ T cells. Irradiation also produces an immunosuppressive effect mediated by tumor-associated macrophages (TAMs) and regulatory T lymphocytes (Tregs), which counterbalances the immunostimulatory effect. In this work, we review the mechanisms involved in the radiation-induced immune response, which support the combined treatment of RT and immunotherapy, focusing, where possible, on gynecologic cancer. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
41. An IL-23-STAT4 pathway is required for the proinflammatory function of classical dendritic cells during CNS inflammation.
- Author
-
Alakhras, Nada S., Wenwu Zhang, Barros, Nicolas, Sharma, Anchal, Ropa, James, Priya, Raj, Yang, X. Frank, and Kaplan, Mark H.
- Subjects
DENDRITIC cells ,STAT proteins ,CENTRAL nervous system ,T cells ,MULTIPLE sclerosis - Abstract
Although many cytokine pathways are important for dendritic cell (DC) development, it is less clear what cytokine signals promote the function of mature dendritic cells. The signal transducer and activator of transcription 4 (STAT4) promotes protective immunity and autoimmunity downstream of proinflammatory cytokines including IL-12 and IL-23. In experimental autoimmune encephalomyelitis (EAE), an animal model of multiple sclerosis (MS), Stat4-/-mice are resistant to the development of inflammation and paralysis. To define whether STAT4 is required for intrinsic signaling in mature DC function, we used conditional mutant mice in the EAE model. Deficiency of STAT4 in CD11c-expressing cells resulted in decreased T cell priming and inflammation in the central nervous system. EAE susceptibility was recovered following adoptive transfer of wild-type bone marrow-derived DCs to mice with STAT4-deficient DCs, but not adoptive transfer of STAT4-or IL-23R-deficient DCs. Single-cell RNA-sequencing (RNA-seq) identified STAT4-dependent genes in DC subsets that paralleled a signature in MS patient DCs. Together, these data define an IL-23-STAT4 pathway in DCs that is key to DC function during inflammatory disease. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
42. Peripheral Blood Mononuclear Cells and Serum Cytokines in Patients with Lupus Nephritis after COVID-19.
- Author
-
Lisowska, Katarzyna A., Ciesielska-Figlon, Klaudia, Komorniczak, Michał, Bułło-Piontecka, Barbara, Dębska-Ślizień, Alicja, and Wardowska, Anna
- Subjects
MONONUCLEAR leukocytes ,COVID-19 ,REGULATORY T cells ,COVID-19 pandemic ,SYSTEMIC lupus erythematosus ,T cells ,B cells - Abstract
Systemic lupus erythematosus (SLE) patients have an increased risk of infections and infection-related mortality. Therefore, during the global SARS-CoV-2 pandemic, SLE patients were particularly vulnerable to SARS-CoV-2 infections. Also, compared to other patients, SLE patients seem to develop more severe manifestations of coronavirus disease 2019 (COVID-19), with higher rates of hospitalization, invasive ventilation requirements, or death. This study evaluated the immune parameters after SARS-CoV-2 infection in SLE patients. We analyzed subpopulations of peripheral blood cells collected from patients with renal manifestation of SLE (lupus nephritis, LN). LN patients were divided into two subgroups: those unexposed to SARS-CoV-2 (LN CoV-2(−)) and those who had confirmed COVID-19 (LN-CoV-2(+)) six months earlier. We analyzed basic subpopulations of T cells, B cells, monocytes, dendritic cells (DCs), and serum cytokines using flow cytometry. All collected data were compared to a healthy control group without SARS-CoV-2 infection in medical history. LN patients were characterized by a decreased percentage of helper T (Th) cells and an increased percentage of cytotoxic T (Tc) cells regardless of SARS-CoV-2 infection. LN CoV-2(+) patients had a higher percentage of regulatory T cells (Tregs) and plasmablasts (PBs) and a lower percentage of non-switched memory (NSM) B cells compared to LN CoV-2(−) patients or healthy controls (HC CoV-2(−)). LN patients had a higher percentage of total monocytes compared with HC CoV-2(−). LN CoV-2(+) patients had a higher percentage of classical and intermediate monocytes than LN CoV-2(−) patients and HC CoV-2(−). LN CoV-2(+) patients had higher serum IL-6 levels than HC CoV-2(−), while LN CoV-2(−) patients had higher levels of serum IL-10. LN patients are characterized by disturbances in the blood's basic immunological parameters. However, SARS-CoV-2 infection influences B-cell and monocyte compartments. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
43. Type I conventional dendritic cells and CD8+ T cells predict favorable clinical outcome of head and neck squamous cell carcinoma patients.
- Author
-
Kirchner, Johanna, Plesca, Ioana, Rothe, Rebecca, Resag, Antonia, Löck, Steffen, Benešová, Iva, Rupp, Luise, Linge, Annett, Wehner, Rebekka, Krause, Mechthild, and Schmitz, Marc
- Subjects
T cells ,REGULATORY T cells ,SQUAMOUS cell carcinoma ,TREATMENT effectiveness ,DENDRITIC cells ,HEAD & neck cancer - Abstract
Head and neck squamous cell carcinoma (HNSCC) is one of the most common tumor entities worldwide, with human papillomavirus (HPV) infection contributing to cancer development. Conventional therapies achieve only limited efficiency, especially in recurrent or metastatic HNSCC. As the immune landscape decisively impacts the survival of patients and treatment efficacy, this study comprehensively investigated the immunological tumor microenvironment (TME) and its association with patient outcome, with special focus on several dendritic cell (DC) and T lymphocyte subpopulations. Therefore, formalin-fixed paraffin-embedded tumor samples of 56 HNSCC patients, who have undergone resection and adjuvant radiotherapy, were analyzed by multiplex immunohistochemistry focusing on the detailed phenotypic characterization and spatial distribution of DCs, CD8
+ T cells, and T-helper cell subsets in different tumor compartments. Immune cell densities and proportions were correlated with clinical characteristics of the whole HNSCC cohort and different HPV- or hypoxia-associated subcohorts. Tumor stroma was highly infiltrated by plasmacytoid DCs and T lymphocytes. Among the T-helper cells and CD8+ T cells, stromal regulatory T cells and intraepithelial exhausted CD8+ T cells expressing programmed cell death protein-1 (PD-1+ ) and/or lymphocyteactivation gene-3 (LAG-3+ ) were the predominant phenotypes, indicating an immunosuppressive TME. HPV-associated tumors showed significantly higher infiltration of type I and type II conventional DCs (cDC1, cDC2) as well as several CD8+ T cell phenotypes including exhausted, activated, and proliferating T cells. On the contrary, tumors with hypoxia-associated gene signatures exhibited reduced infiltration for these immune cells. By multivariate Cox regression, immune-related prognostic factors were identified. Patient clusters defined by high infiltration of DCs and T lymphocytes combined with HPV positivity or low hypoxia showed significantly prolonged survival. Thereby, cDC1 and CD8+ T cells emerged as independent prognostic factors for local and distant recurrence. These results might contribute to the implementation of an immune cell infiltration score predicting HNSCC patients' survival and such patient stratification might improve the design of future individualized radiochemo- (immuno)therapies. [ABSTRACT FROM AUTHOR]- Published
- 2024
- Full Text
- View/download PDF
44. Characterising plasmacytoid and myeloid AXL+ SIGLEC-6+ dendritic cell functions and their interactions with HIV.
- Author
-
Warner van Dijk, Freja A., Tong, Orion, O'Neil, Thomas R., Bertram, Kirstie M., Hu, Kevin, Baharlou, Heeva, Vine, Erica E., Jenns, Kate, Gosselink, Martijn P., Toh, James W., Papadopoulos, Tim, Barnouti, Laith, Jenkins, Gregory J., Sandercoe, Gavin, Haniffa, Muzlifah, Sandgren, Kerrie J., Harman, Andrew N., Cunningham, Anthony L., and Nasr, Najla
- Subjects
CELL physiology ,DENDRITIC cells ,HIV ,HIV infection transmission ,HIV infections ,T cells ,CXCR4 receptors ,CHEMOKINE receptors - Abstract
AXL
+ Siglec-6+ dendritic cells (ASDC) are novel myeloid DCs which can be subdivided into CD11c+ and CD123+ expressing subsets. We showed for the first time that these two ASDC subsets are present in inflamed human anogenital tissues where HIV transmission occurs. Their presence in inflamed tissues was supported by single cell RNA analysis of public databases of such tissues including psoriasis diseased skin and colorectal cancer. Almost all previous studies have examined ASDCs as a combined population. Our data revealed that the two ASDC subsets differ markedly in their functions when compared with each other and to pDCs. Relative to their cell functions, both subsets of blood ASDCs but not pDCs expressed co-stimulatory and maturation markers which were more prevalent on CD11c+ ASDCs, thus inducing more T cell proliferation and activation than their CD123+ counterparts. There was also a significant polarisation of naïve T cells by both ASDC subsets toward Th2, Th9, Th22, Th17 and Treg but less toward a Th1 phenotype. Furthermore, we investigated the expression of chemokine receptors that facilitate ASDCs and pDCs migration from blood to inflamed tissues, their HIV binding receptors, and their interactions with HIV and CD4 T cells. For HIV infection, within 2 hours of HIV exposure, CD11c+ ASDCs showed a trend in more viral transfer to T cells than CD123+ ASDCs and pDCs for first phase transfer. However, for second phase transfer, CD123+ ASDCs showed a trend in transferring more HIV than CD11c+ ASDCs and there was no viral transfer from pDCs. As anogenital inflammation is a prerequisite for HIV transmission, strategies to inhibit ASDC recruitment into inflamed tissues and their ability to transmit HIV to CD4 T cells should be considered. Author summary: This study highlights the significance of AXL+ Siglec-6+ dendritic cells (ASDC) in HIV transmission, particularly in inflamed peripheral tissues such as anogenital tissues, where HIV transmission is prevalent. It reveals that ASDCs are present in inflamed human tissues, including psoriasis affected skin, colorectal cancer and anogenital tissues. However, they are absent in uninflamed tissues. Furthermore, we investigated the expression of chemokine receptors that facilitate ASDC migration from blood to inflamed tissues, and their interactions with HIV and CD4 T cells. Notably, different subsets of ASDCs exhibit different expression levels of HIV binding receptors and showed trends of different phases of HIV transmission to T cells. Understanding ASDC involvement in HIV transmission could provide valuable insights for developing strategies to inhibit their recruitment to inflamed tissues and their ability to transmit the virus to CD4 T cells, potentially offering new avenues for HIV prevention and treatment. [ABSTRACT FROM AUTHOR]- Published
- 2024
- Full Text
- View/download PDF
45. Synergistic antitumor immune response mediated by paclitaxelconjugated nanohybrid oncolytic adenovirus with dendritic cell therapy.
- Author
-
In-Wook Kim, A-Rum Yoon, JinWoo Hong, Kasala, Dayananda, and Chae-Ok Yun
- Subjects
IMMUNE response ,REGULATORY T cells ,DENDRITIC cells ,TUMOR-infiltrating immune cells ,CELLULAR therapy ,ADENOVIRUS diseases ,PULMONARY alveolar proteinosis - Abstract
Dendritic cell (DC)-based vaccines have emerged as a promising strategy in cancer immunotherapy due to low toxicity. However, the therapeutic efficacy of DC as a monotherapy is insufficient due to highly immunosuppressive tumor environment. To address these limitations of DC as immunotherapeutic agent, we have developed a polymeric nanocomplex incorporating (1) oncolytic adenovirus (oAd) co-expressing interleukin (IL)-12 and granulocyte-macrophage colonystimulating factor (GM-CSF) and (2) arginine-grafted bioreducible polymer with PEGylated paclitaxel (APP) to restore antitumor immune surveillance function in tumor milieu and potentiate immunostimulatory attributes of DC vaccine. Nanohybrid complex (oAd/APP) in combination with DC (oAd/APP+DC) induced superior expression level of antitumor cytokines (IL-12, GM-CSF, and interferon gamma) than either oAd/APP or DC monotherapy in tumor tissues, thus resulting in superior intratumoral infiltration of both endogenous and exogenous DCs. Furthermore, oAd/APP+DC treatment led superior migration of DC to secondary lymphoid organs, such as draining lymph nodes and spleen, in comparison with either monotherapy. Superior migration profile of DCs in oAd/APP+DC treatment group resulted in more prolific activation of tumor-specific T cells in these lymphoid organs and greater intratumoral infiltration of T cells. Additionally, oAd/ APP+DC treatment led to lower subset of tumor infiltrating lymphocytes and splenocytes being immunosuppressive regulatory T cells than any other treatment groups. Collectively, oAd/APP+DC led to superior induction of antitumor immune response and amelioration of immunosuppressive tumor microenvironment to elicit potent tumor growth inhibition than either monotherapy. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
46. Myelin Oligodendrocyte Glycoprotein (MOG)35–55 Mannan Conjugate Induces Human T-Cell Tolerance and Can Be Used as a Personalized Therapy for Multiple Sclerosis.
- Author
-
Rodi, Maria, de Lastic, Anne-Lise, Panagoulias, Ioannis, Aggeletopoulou, Ioanna, Kelaidonis, Kostas, Matsoukas, John, Apostolopoulos, Vasso, and Mouzaki, Athanasia
- Subjects
T cells ,MYELIN oligodendrocyte glycoprotein ,IMMUNOLOGIC memory ,MULTIPLE sclerosis ,REGULATORY T cells ,CELL culture ,T cell receptors ,CELL populations - Abstract
We have previously performed preclinical studies with the oxidized mannan-conjugated peptide MOG35–55 (OM-MOG35–55) in vivo (EAE mouse model) and in vitro (human peripheral blood) and demonstrated that OM-MOG35–55 suppresses antigen-specific T cell responses associated with autoimmune demyelination. Based on these results, we developed different types of dendritic cells (DCs) from the peripheral blood monocytes of patients with multiple sclerosis (MS) or healthy controls presenting OM-MOG35–55 or MOG-35–55 to autologous T cells to investigate the tolerogenic potential of OM-MOG35–55 for its possible use in MS therapy. To this end, monocytes were differentiated into different DC types in the presence of IL-4+GM-CSF ± dexamethasone (DEXA) ± vitamin D3 (VITD3). At the end of their differentiation, the DCs were loaded with peptides and co-cultured with T cells +IL-2 for 4 antigen presentation cycles. The phenotypes of the DC and T cell populations were analyzed using flow cytometry and the secreted cytokines using flow cytometry or ELISA. On day 8, the monocytes had converted into DCs expressing the typical markers of mature or immature phenotypes. Co-culture of T cells with all DC types for 4 antigen presentation cycles resulted in an increase in memory CD4+ T cells compared to memory CD8+ T cells and a suppressive shift in secreted cytokines, mainly due to increased TGF-β1 levels. The best tolerogenic effect was obtained when patient CD4+ T cells were co-cultured with VITD3-DCs presenting OM-MOG35–55, resulting in the highest levels of CD4+PD-1+ T cells and CD4+CD25+Foxp3+ Τ cells. In conclusion, the tolerance induction protocols presented in this work demonstrate that OM-MOG35–55 could form the basis for the development of personalized therapeutic vaccines or immunomodulatory treatments for MS. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
47. Nuclear factor-?B1 controls the functional maturation of dendritic cells and prevents the activation of autoreactive T cells.
- Author
-
Dissanayake, Dilan, Hall, Håkan, Berg-Brown, Nancy, Elford, Alisha R, Hamilton, Sara R, Murakami, Kiichi, Deluca, Leslie Summers, Gommerman, Jennifer L, and Ohashi, Pamela S
- Subjects
T cells ,AUTOIMMUNITY ,IMMUNE response ,ANTINEOPLASTIC agents ,TUMOR necrosis factors ,DENDRITIC cells - Abstract
Mature dendritic cells (DCs) are crucial for the induction of adaptive immune responses and perturbed DC homeostasis can result in autoimmune disease. Either uncontrolled expansion or enhanced survival of DCs can result in a variety of autoimmune diseases in mouse models. In addition, increased maturation signals, through overexpression of surface Toll-like receptors (TLRs) or stimulation by type I interferon (IFN), has been associated with systemic autoimmunity. Whereas recent studies have focused on identifying factors required for initiating the maturation process, the possibility that resting DCs also express molecules that 'hold' them in an immature state has generally not been considered. Here we show that nuclear factor-?B1 (NF-?B1) is crucial for maintaining the resting state of DCs. Self-antigen-pulsed unstimulated DCs that do not express NF-?B1 were able to activate CD8
+ T lymphocytes and induce autoimmunity. We further show that NF-?B1 negatively regulates the spontaneous production of tumor necrosis factor-? (TNF-?), which is associated with increased granzyme B expression in cytotoxic T lymphocytes (CTLs). These findings provide a new perspective on functional DC maturation and a potential mechanism that may account for pathologic T cell activation. [ABSTRACT FROM AUTHOR]- Published
- 2011
- Full Text
- View/download PDF
48. Exhausted mature dendritic cells exhibit a slower and less persistent random motility but retain chemotaxis against CCL19.
- Author
-
Choi, Yongjun, Sunkara, Vijaya, Lee, Yeojin, and Cho, Yoon-Kyoung
- Subjects
DENDRITIC cells ,CHEMOTAXIS ,CELL motility ,T cells ,SPACE exploration ,LYMPH nodes ,IMMUNE response ,ANTIGENS - Abstract
Dendritic cells (DCs), which are immune sentinels in the peripheral tissues, play a number of roles, including patrolling for pathogens, internalising antigens, transporting antigens to the lymph nodes (LNs), interacting with T cells, and secreting cytokines. The well-coordinated migration of DCs under various immunological or inflammatory conditions is therefore essential to ensure an effective immune response. Upon maturation, DCs migrate faster and more persistently than immature DCs (iDCs), which is believed to facilitate CCR7-dependent chemotaxis. It has been reported that lipopolysaccharide-activated DCs produce IL-12 only transiently, and become resistant to further stimulation through exhaustion. However, little is known about the influence of DC exhaustion on cellular motility. Here, we studied the cellular migration of exhausted DCs in tissue-mimicked confined environments. We found that the speed of exhausted matured DCs (xmDCs) decreased significantly compared to active matured DCs (amDCs) and iDCs. In contrast, the speed fluctuation increased compared to that of amDCs and was similar to that of iDCs. In addition, the diffusivity of the xmDCs was significantly lower than that of the amDCs, which implies that DC exhaustion reduces the space exploration ability. Interestingly, CCR7-dependent chemotaxis against CCL19 in xmDCs was not considerably different from that observed in amDCs. Taken together, we report a unique intrinsic cell migration behaviour of xmDCs, which exhibit a slower, less persistent, and less diffusive random motility, which results in the DCs remaining at the site of infection, although a well-preserved CCR7-dependent chemotactic motility is maintained. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
49. Combination therapy of cancer with cancer vaccine and immune checkpoint inhibitors: A mathematical model.
- Author
-
Lai, Xiulan and Friedman, Avner
- Subjects
COMBINATION drug therapy ,CANCER treatment ,CANCER vaccines ,DRUG administration ,CANCER cells ,DENDRITIC cells ,MATHEMATICAL models - Abstract
In this paper we consider a combination therapy of cancer. One drug is a vaccine which activates dendritic cells so that they induce more T cells to infiltrate the tumor. The other drug is a checkpoint inhibitor, which enables the T cells to remain active against the cancer cells. The two drugs are positively correlated in the sense that an increase in the amount of each drug results in a reduction in the tumor volume. We consider the question whether a treatment with combination of the two drugs at certain levels is preferable to a treatment by one of the drugs alone at ‘roughly’ twice the dosage level; if that is the case, then we say that there is a positive ‘synergy’ for this combination of dosages. To address this question, we develop a mathematical model using a system of partial differential equations. The variables include dendritic and cancer cells, CD4
+ and CD8+ T cells, IL-12 and IL-2, GM-CSF produced by the vaccine, and a T cell checkpoint inhibitor associated with PD-1. We use the model to explore the efficacy of the two drugs, separately and in combination, and compare the simulations with data from mouse experiments. We next introduce the concept of synergy between the drugs and develop a synergy map which suggests in what proportion to administer the drugs in order to achieve the maximum reduction of tumor volume under the constraint of maximum tolerated dose. [ABSTRACT FROM AUTHOR]- Published
- 2017
- Full Text
- View/download PDF
50. Skin sensitizers in cosmetics and beyond: potential multiple mechanisms of action and importance of T-cell assays for in vitro screening.
- Author
-
Vukmanović, Stanislav and Sadrieh, Nakissa
- Subjects
CONTACT dermatitis ,ALLERGIES ,COSMETICS ,ANTIGENS ,T cells ,ALLERGENS - Abstract
Allergic contact dermatitis (ACD) is a delayed-type hypersensitivity (DTH) reaction induced by repeated contact with sensitizers. The ability of a chemical to act as a sensitizer has most frequently been tested in animals. As the use of animals for these purposes is gradually and globally being phased out, there is a need for reliable in vitro surrogate assays. Currently proposed in vitro assays are designed to test four key events of the adverse outcome pathway (AOP) involving covalent modification of self-proteins by sensitizers (haptenation) and presentation of new antigens (hapten/carrier complexes) to the immune system. There appears to be imperfect alignment of in vitro assays with clinical and/or animal data, suggesting possibly additional mechanisms of ACD development. Indeed, studies on allergies to small drugs, small chemical-induced HLA-peptide exchange for vaccination purposes and cosmetic ingredient-induced exposure of autoantigens suggest a possibility of DTH response promotion by hapten/carrier-independent mechanisms. Therefore, there is a need for additional appropriate in vitro assays, in order to achieve maximal concordance between clinical and/or animal data and in vitro assays. In this paper, we will review evidence supporting the idea of diverse mechanisms of ACD development. We will also discuss the impact of these multiple mechanisms, on the AOP and on the in vitro assays that should be used for allergen detection. We will propose alloreactivity-like reactions, aided by computer modeling and biochemical tests of compound-HLA binding, as additional tools for better prediction of DTH reactions, resulting from exposure to ingredients in cosmetic products. The combination of the proposed tests, along with the existing assays, should further enhance animal-free assessment of sensitizing potential of individual chemicals. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.